CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers. The newly acquired IP, which includes U.S. Patent No. 11,788,057 B2, allows NeOnc to create highly sophisticated, patient-derived 3D brain tumor models. By applying proprietary AI and quantum modeling algorithms to these realistic biological environments, the company can now perform high-throughput...

A1R WATER builds, owns and operates water farms and bottling plants where they package and sell finished beverage products to a marquee list of hotels, real estate developers, events venues and sports teamsProposed transaction values A1R WATER at a pro forma enterprise value of $419 millionProposed transaction includes a fully committed PIPE investment $63.5 million, $32.5 million of which was funded at signing of the Business Combination AgreementPIPE investment led by SPAC sponsor Inflection Point Asset Management includes strategic investment from new shareholders including Southern Glazer’s Wine & Spirits through its corporate growth, venture, and strategic acquisitions arm, SG Ventures; these partners join existing investors including Tau Capital, anchored by the Royal Group of Abu Dhabi, which has been A1R WATER’s largest...

New Acquisitions Expected to Drive Total Annual Revenues to $100M and Expand Operating Profit Hauppauge, NY, Aug. 25, 2025 (GLOBE NEWSWIRE) — Cemtrex Inc. (Nasdaq: CETX), a diversified industrial and technology company, today announced it has signed non-binding letters of intent to acquire two profitable U.S.-based businesses — one in industrial robotics integration and the other in aerospace and defense systems engineering. Combined, the two companies are expected to contribute $15–18 million in annual revenue and $2.5–3 million in operating income on a go forward basis, once closed and integrated. “These potential acquisitions directly align with our long-term strategy to expand into high-value markets with strong macro tailwinds,” said Saagar Govil, Chairman and CEO. “We believe both businesses bring meaningful scale, margin,...

Acquisition Proposal is Fully Financed and Requires No Further Diligence—Ready for Definitive Documents Prepared to Improve Offer Upon Constructive Engagement from Board BIRMINGHAM, Ala., Aug. 25, 2025 (GLOBE NEWSWIRE) — Forager Capital Management (“Forager”), one of the largest shareholders of Quipt Home Medical Corp. (“Quipt”) (NASDAQ: QIPT; TSX: QIPT), with beneficial ownership of 9.7%, today announced it has submitted a proposal to acquire all outstanding shares of Quipt for $3.10 per share in cash (the “Acquisition Proposal”). The Acquisition Proposal is not subject to any due diligence or financing conditions and is capable of being executed immediately. The offer represents a 120% premium to Quipt’s unaffected share price of $1.41 at close on May 19, 2025, the trading day prior to Forager’s prior proposal being made public. In...

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Danforth Advisors, LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and execution from company incubation to approval. The team’s expertise spans discovery, early to late stage non-clinical and clinical development, translational sciences, and all areas of CMC with full program and alliance management oversight across all major modalities and therapeutic areas. Michelle Higgin, PhD, will continue in her role as CEO. “PharmaDirections and...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025.   The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).  Trading day No. of shares Average price Amount    Accumulated until 15 August 2025 99,500 597.56 59,457,510    Monday, 18 August 2025 2,000 582.18 1,164,360    Tuesday, 19 August 2025 1,500 603.63 905,445    Wednesday, 20 August 2025 1,500 600.17 900,255    Thursday, 21 August 2025 1,500 597.75 896,625    Friday,...

SINGAPORE, Aug. 25, 2025 (GLOBE NEWSWIRE) — GCL Global Holdings Ltd (NASDAQ: GCL) (“GCL”), a leading provider of games and entertainment and the indirect parent company of Epicsoft Asia Pte. Ltd. (“Epicsoft Asia” or “Offeror”), today announced that Epicsoft Asia has completed the compulsory acquisition of Ban Leong Technologies Limited (“Ban Leong”) on August 25, 2025, and Ban Leong will be delisted from the Singapore Stock Exchange on August 26, 2025. For over three decades, Ban Leong has been a leading distributor of technology products across Asia, offering an extensive portfolio that includes IT accessories, gaming components, smart (IoT) devices, and commercial solutions. The company is an authorized distributor for more than 50 globally recognized brands, including Razer, Nvidia, Samsung, Huawei, TP-Link, and LG. Leveraging...

TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) — Volaris Group today announced the acquisition of Maze Feedback AS, a Norway-based Software-as-a-Service company that offers customer experience (CX) software to retailers to turn customer feedback into actionable insights. The company has 20+ years of experience in retail consulting and the improvement of store teams in the Nordics and the United Kingdom. “We are happy to have Maze Feedback AS find a home in Volaris Group,” says Janni Løber Zesach, Group Leader, Volaris Group. “Maze Feedback AS has shown success in the retail vertical market, and we look forward to combining our shared knowledge and expertise to facilitate frontline retail training. By capitalizing on the Volaris network, we hope to pursue a data-driven culture through best-practice sharing.” The company was founded in...

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals’ 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals’ closing price on August 22, 2025 Strengthens organization by integrating scPharmaceuticals’ established commercial and medical capabilities into MannKind’s existing infrastructure FUROSCIX ReadyFlow Autoinjector on track for Q3 2025...

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals’ 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals’ closing price on August 22, 2025 Strengthens organization by integrating scPharmaceuticals’ established commercial and medical capabilities into MannKind’s existing infrastructure FUROSCIX ReadyFlow Autoinjector on track for Q3 2025...